伊布替尼，一种布鲁顿酪氨酸激酶抑制剂，一种新型隐球菌病的危险因素。
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
机构信息
Infectious diseases department, CHU de Nantes, 1, place Alexis Ricordeau, 44093 Nantes cedex, France; INSERM CIC 1413, CHU de Nantes, Nantes, France.
Parasitology and medical mycology laboratory, CHU de Nantes, Nantes, France; Nantes Atlantique Universities, EA1155 IICiMed, Institut de Recherche en Santé 2, Nantes, France.
出版信息
Med Mal Infect. 2020 Nov;50(8):742-745. doi: 10.1016/j.medmal.2020.07.005. Epub 2020 Aug 7.
PURPOSE
Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor.
PATIENTS AND METHOD
We reported three additional cases and reviewed 16 previous published cases together with cases from the international pharmacovigilance database.
RESULTS
Patients were mainly treated for chronic lymphocytic leukemia. Cryptococcosis mostly occurred during the first six months (66%) and especially the first two months (44%) of treatment. Clinical presentation is often pulmonary (68%) and the outcome is usually favorable despite ibrutinib continuation.
CONCLUSION
Clinicians must be aware of this infection in patients with hematological malignancies on ibrutinib.
目的
布鲁顿酪氨酸激酶抑制剂伊布替尼在治疗血液系统恶性肿瘤患者中的应用越来越广泛，侵袭性真菌感染（尤其是新型隐球菌感染）的报道也越来越多。
患者和方法
我们报道了另外 3 例病例，并对国际药物警戒数据库中的 16 例既往已发表病例和 3 例本中心病例进行了复习。
结果
患者主要接受伊布替尼治疗慢性淋巴细胞白血病。隐球菌病主要发生在治疗的前 6 个月（66%），尤其是前 2 个月（44%）。临床表现通常为肺部（68%），尽管继续使用伊布替尼，但预后通常较好。
结论
血液系统恶性肿瘤患者接受伊布替尼治疗时，临床医生必须警惕这种感染。
Zotero 插件